ClinicalTrials.gg
RecruitingNCT05159284Updated Mar 13, 2024

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

A Phase 4 interventional study of Hydrocortisone Ophthalmic and MGD Rx EyeBag® eyelid warming device in Dry Eye and Meibomian Gland Dysfunction, sponsored by Laboratorios Thea, Spain. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Laboratorios Thea, Spain · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Planned enrollment
23rd of 41
54 · median 60
Started
2021
with 3 others
Phase 4
5 of 44
2 open now
Registered
24th of 44
by date
Lead sponsor
2 of 44
Laboratorios Thea, Spain

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 23rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 4, and was the 24th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is assess the efficacy and safety of topical hydrocortisone (Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated with moderate meibomian gland dysfunction.

Read the detailed description

This is a prospective, interventional, randomized (1:1), single blind, of parallel groups and two treatment arms clinical trial (phase IV).

All patients diagnosed with dry eye disease (DED) associated with moderate MGD may participate in the study if they meet all the selection criteria.

Patients (or their representatives) will provide informed consent (IC) prior to the enrolment in the study and to the start of data collection. Patients must meet all the inclusion criteria and not meet any of the exclusion criteria.

03

Conditions studied

  • Dry Eye
  • Meibomian Gland Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Documented diagnosis of DE defined by TBUT value ≤ 5 seconds and Schirmer I test value \< 10 mm/5 min
  3. Normal ophthalmic findings except dry eye disease and meibomian gland dysfunction
  4. OSDI score > 23 (moderate symptoms)
  5. Documented diagnosis of MGD grade 2 to 3
  6. Patient who can understand the instructions and adhere to medications
  7. Patient who receives complete information regarding the study objectives, authorize their participation in the study and sign an form before entering in the study

Exclusion criteria

Exclusion Criteria:

  1. Any or known allergies to Lephanet®, Thealoz Duo®, MGD Rx EyeBag® or Softacort®
  2. Ocular surgery in the past 6 months
  3. Ocular hypertension or glaucoma
  4. Cicatricial MGD
  5. Atopic condition including ocular allergy
  6. Suspect demodex lid infestation as evidenced by the presence of collarettes
  7. Intraocular inflammation
  8. Confirmed infection with COVID-19 in the last 3 months
  9. Systemic disorder
  10. Use of contact lenses during the month prior to inclusion in the study or during the study
  11. Punctal occlusion
  12. Intraocular pressure > 22 mmHg
  13. Patient who has received topical or systemic anti-inflammatory treatments including and nonsteroidal anti-inflammatory drugs (NSAIDS) within 3 months prior to be included in the study or with a prescription for receiving topical / systemic anti-inflammatory treatments for the next 3 months
  14. In the investigator´s opinion, use of systemic medications that could affect the function of the meibomian gland and tear production within 3 months prior to be included in the study
  15. Any ocular or systemic disease known to affect the tear film other than MGD
  16. Patient with any situation or state that in the opinion of the investigator discourages their participation in the study
  17. Patient participating in any other interventional or non-interventional study or who have participated in another study within 30 days prior to inclusion in this study
  18. Women who are pregnant, planning to become pregnant or breastfeeding
  19. Patient who will not be able to complete the study (e.g., not willing to attend the follow-up visits, way of life interfering with compliance)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Softacort® Lephanet® Thealoz Duo® MGD Rx EyeBag®

    Drug: Hydrocortisone Ophthalmic · Device: MGD Rx EyeBag® eyelid warming device · Device: Lephanet® lid wipes · Device: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%

  • Other
    Control group

    Lephanet® Thealoz Duo® MGD Rx EyeBag®

    Device: MGD Rx EyeBag® eyelid warming device · Device: Lephanet® lid wipes · Device: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%

Interventions

  • DrugHydrocortisone Ophthalmic

    1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.

    Also known as: Softacort®

  • DeviceMGD Rx EyeBag® eyelid warming device

    Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.

    Also known as: Blepha EyeBag®

  • DeviceLephanet® lid wipes

    Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.

    Also known as: Blephaclean®

  • DeviceThealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%

    Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.

06

What researchers measure

Primary outcomes

  1. Efficacy endpoint: Change from baseline in Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) at 14 days

    Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) calculated by the sum of the Visual Analogue scale (VAS) score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in the following symptoms: itching, dry eye sensation, burning, foreign body sensation and ocular redness.

    Time frame: Day 0 and Day 14

  2. Safety endpoint: Incidence of increased intraocular pressure and change from baseline at Day 0, Day 14, Day 28 and Day 84

    Mean of 3 measures of intraocular pressure measured with Goldmann tonometer in each eye on Day 0, Day 14, Day 28 and Day 84. Increased intraocular pressure defined as \>21 mmHg.

    Time frame: Day 0, Day 14, Day 28 and Day 84

Secondary outcomes

  1. Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire at Day 14, Day 28 and Day 84

    12-item questionnaire related to vision-related function, ocular symptoms, and environmental triggers of dry eye. Response on a 0 to 4 scale that ranges from "none of the time" to "all of the time". The final score is calculated by multiplying the sum of all the scores by 25 and then dividing the total by the number of questions answered. Scores range from 0 to 100 with 0 to 12 representing normal, 13 to 22 mild DED, 23 to 32 moderate DED, and 33 severe DED

    Time frame: Day 0, Day 14, Day 28 and Day 84.

  2. Change from baseline in Meibomian Gland Dysfunction Dry Eye symptom score at Day 14, Day 28 and Day 84

    Meibomian Gland Dysfunction Dry Eye symptom score (MGD-DE) calculated by the sum of the VAS score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in the following symptoms: itching, dry eye sensation, burning, foreign body sensation and ocular redness.

    Time frame: Day 0, Day 14, Day 28 and Day 84.

  3. Change from baseline in ocular symptoms Visual Analogue scale (VAS) questionnaire at Day 14, Day 28 and Day 84

    VAS score assigned by the patient on a scale from 0 (no symptoms) to 100 (worst symptoms) in each of the following symptoms: itching, dry eye sensation, burning, foreign body sensation, ocular redness, ocular fatigue, and blurry vision.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  4. Change from baseline in hyperemia score (McMonnies-Chapman scale) at Day 14, Day 28 and Day 84.

    Inferior conjunctival hyperemia will be estimated by comparison with the photographic conjunctival hyperemia reference scale covering six grades, with highest grade as worst hyperemia.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  5. Change from baseline in Tear break up time (TBUT) at Day 14, Day 28 and Day 84

    Number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film observed with slit-lamp after instillation of fluorescein. A TBUT under 10 seconds is considered abnormal

    Time frame: Day 0, Day 14, Day 28 and Day 84

  6. Change from baseline in corneal and conjunctival staining with fluorescein (Oxford grading scale) at Day 14, Day 28 and Day 84

    After instillation of fluorescein in conjunctival sac a comparison to the Oxford chart panels A to E, with E being the worst outcome.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  7. Change from baseline in corneal and conjunctival staining with lissamine green (Van Bijsterveld scale) at Day 14, Day 28 and Day 84

    Scoring system that divides the ocular surface into three zones: nasal bulbar conjunctiva, temporal bulbar conjunctiva, and cornea. Each zone is evaluated on a scale of 0 to 3, with 0 indicating no staining and 3 indicating confluent staining; the maximum possible worse outcome score with this system is 9.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  8. Change from baseline in meniscus height at Day 14, Day 28 and Day 84

    Measured with anterior segment optical coherence tomography. The lower the tear meniscus height the worst outcome.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  9. Change from baseline in Schirmer I test at Day 14, Day 28 and Day 84

    Folded edge Schirmer strip is placed over the rim of the lower eyelid and the eyes are then lightly closed. The amount of wetting after 5 minutes on the strip is measured in mm. Normal more than 10 mm / 5 min

    Time frame: Day 0, Day 14, Day 28 and Day 84

  10. Change from baseline in MGD grading at Day 14, Day 28 and Day 84

    Grading of MGD: 0 to 4 where 0 is no meibomian gland dropout and expressed meibum with clear appearance and 4 is with gland dropout of more than half the lid margin or complete keratinization of the ducts and no expression of meibum. Higher grade is a worse outcome.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  11. Change from baseline in lid abnormalities at Day 14, Day 28 and Day 84

    Lid margin irregularity (presence or absence), thickness, and plugging of the meibomian orifices. A scale from 0 to 2, with 0 = no findings, 1 = mild findings, and 2 = severe findings.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  12. Change from baseline in Eyelid telangiectasia score at Day 14, Day 28 and Day 84

    Eyelid telangiectasia score from 0 to 3, where 0 is no findings and 3 is severe findings.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  13. Change from baseline in Lissamine green staining score at Day 14, Day 28 and Day 84

    Mean of longitudinal staining of upper lid margin after instilation with lissamine green graded from 0 to 3 and sagittal staining graded from 0 to 3 estimated by comparison with standard chart. Higher grade is a worse outcome.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  14. Change from baseline in Meibomian gland expressibility score at Day 14, Day 28 and Day 84

    Express each of 5 glands in temporal, central and lower lid and grade each gland on a scale from 0 to 3, with 3 = clear liquid secretion, 2 = cloudy liquid secretion, 1 = inspissated / toothpaste consistency, and 0 = no secretion. Total score range from 0 to 45. A lower grade is a worse outcome.

    Time frame: Day 0, Day 14, Day 28 and Day 84

  15. Change from baseline in tear inflammatory cytokines at Day 14

    Levels of 8 inflammatory cytokines in tears will be determined 2 micro liter samples taken from each eye.

    Time frame: Day 0 and Day 14.

  16. Incidence of adverse events and serious adverse events occurred during the study.

    Report of any untoward medical occurrence in a patient during the study

    Time frame: Day 0, Day 14, Day 28 and Day 84

  17. Change from baseline in ETDRS visual acuity at Day 14, Day 28 and Day 84

    Best corrected visual acuity in each eye measured with the ETDRS optotype.

    Time frame: Day 0, Day 14, Day 28 and Day 84

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2024, 37 months after the start.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's planned 37 months is above that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Dec 16, 2021
StartActual
Nov 9, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Mar 2025
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05159284
Lead sponsor
Laboratorios Thea, Spain
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Nov 9, 2021
Primary completion
Dec 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Mar 13, 2024

Study contacts

Maria Beatriz Greaves, Dr
Contact
maría.greaves@theapharma.com
+34934766810 ext. 126
Ana Hervas Ontiveros, Dr
principal investigator · anheront@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion